- For Clinical Research: the case puts post-lock data handling, unblinding and analysis governance under intense scrutiny.
- For Regulatory Affairs: it shows how undisclosed changes to pivotal data can affect an existing marketing authorization.
- For QA and Data Integrity teams: it demonstrates that data credibility can become a product-level regulatory issue, not simply a documentation concern.
EMA Flags Tavneos Trial Data; Post-Lock Changes Undermine Study Reliability
Tavneos, or avacopan, was developed by ChemoCentryx before Amgen acquired the company in 2022. European regulators began reviewing the medicine after concerns emerged about data handling in the pivotal Phase 3 ADVOCATE trial. The CHMP eventually concluded that the study had been conducted in breach of Good Clinical Practice principles and that the data submitted during the original authorization process could no longer be relied upon to demonstrate efficacy.
The key sequence occurred after the study database had been locked. According to BioSpace’s account of the EMA findings, ChemoCentryx study personnel gained access to unblinded efficacy results and saw that superiority at week 52 had not been demonstrated. Data from nine patients were then re-adjudicated, after which the primary analysis changed from a non-significant result to a statistically significant result.
Nine Patient Re-Adjudications Shifted Tavneos’ Week-52 Result
The regulatory concern went beyond the revised analysis itself. According to the EMA findings reported by BioSpace, the changes were not disclosed to regulators, while the clinical study report stated that the protocol-defined unblinding process had been followed.
EMA said it could not isolate the effect of the breach to only part of the data package. Therefore, the regulator concluded that the pivotal study as a whole could no longer support a reliable demonstration of Tavneos’ effectiveness. The CHMP consequently determined that a positive benefit-risk balance could no longer be established.
Professional scenario: If a pivotal analysis changes after database lock and unblinding, what documented controls would your organization require before accepting, rerunning or submitting that analysis?
EU Revokes Tavneos Approval as Trial Data Integrity Concerns Escalate
The European Commission adopted the CHMP recommendation and revoked Tavneos’ marketing authorization on August 6. CSL Vifor said Tavneos would no longer be available for prescribing in the EU and EEA and that existing patients should discuss alternative treatment options with their physicians.
The case also remains active in the United States. FDA has proposed withdrawing Tavneos approval, stating that new information undermines the evidence of effectiveness and raises concerns about material statements in the original application. Tavneos remains on the US market while the regulatory process continues.
What Clinical, QA and Regulatory Teams Should Check After the Tavneos Data Integrity Findings
Teams can draw four immediate actions directly from the case. First, review governance around database lock and access to unblinded data. Second, ensure that re-adjudication and post-hoc analyses have documented justification and independent oversight. Third, verify that material analytical changes are consistently reflected in regulatory submissions and clinical study reports. Finally, confirm that sponsor oversight can reconstruct who accessed data, what changed and why.
Next, regulatory teams should watch the US proceedings closely. FDA has stated that, following a hearing request, the Commissioner will determine whether a hearing should occur and ultimately whether US approval should be withdrawn.
Could Weak Data Governance Put an Approved Drug at Regulatory Risk?
Cases like Tavneos show why quality governance must connect data integrity, investigation, oversight and corrective action rather than treating them as separate controls. Zamann Pharma’s Quality Management System support can provide a useful reference for teams reviewing how CAPA, deviations and audit oversight operate across their quality framework, without waiting for a regulatory event to expose weaknesses.
Source: Biospace.Com